Literature DB >> 20554302

High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays.

Martha Luevano1, Hans-Ulrich Bernard, Hugo A Barrera-Saldaña, Victor Trevino, Alejandro Garcia-Carranca, Luisa L Villa, Bradley J Monk, Xiaolin Tan, D Huw Davies, Phil L Felgner, Mina Kalantari.   

Abstract

We have developed microarrays with all eight proteins encoded by 13 different human papillomavirus types associated with anogenital cancer (HPV-16, -18, -31, -33, -35, -45, and -53), genital warts (HPV-6 and -11), or skin lesions (HPV-1, -2, -4, and -5). We analyzed the seroprevalence of antibodies in 546 patients, which had either cervical carcinomas, or precursor lesions, or which were asymptomatic. All patient groups contained sera ranging from high reactivity against multiple HPV proteins to low or no reactivity. Computational analyses showed the E7 proteins of carcinogenic HPV types as significantly more reactive in cancer patients compared to asymptomatic individuals and discriminating between cancer and HSIL or LSIL patients. Antibodies against E4 and E5 had the highest seroprevalence but did not exhibit differential reactivity relative to pathology. Our study introduces a new approach to future evaluation of the overall antigenicity of HPV proteins and cross-reaction between homologous proteins. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20554302      PMCID: PMC2914195          DOI: 10.1016/j.virol.2010.05.011

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  41 in total

1.  Identification of humoral immune responses in protein microarrays using DNA microarray data analysis techniques.

Authors:  Suman Sundaresh; Denise L Doolan; Siddiqua Hirst; Yunxiang Mu; Berkay Unal; D Huw Davies; Philip L Felgner; Pierre Baldi
Journal:  Bioinformatics       Date:  2006-04-27       Impact factor: 6.937

2.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.

Authors:  Luisa L Villa; Kevin A Ault; Anna R Giuliano; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Darron R Brown; Alex Ferenczy; Diane M Harper; Laura A Koutsky; Robert J Kurman; Matti Lehtinen; Christian Malm; Sven-Eric Olsson; Brigitte M Ronnett; Finn Egil Skjeldestad; Margareta Steinwall; Mark H Stoler; Cosette M Wheeler; Frank J Taddeo; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Rocio Marchese; Mark T Esser; Janine Bryan; Kathrin U Jansen; Heather L Sings; Gretchen M Tamms; Alfred J Saah; Eliav Barr
Journal:  Vaccine       Date:  2006-05-15       Impact factor: 3.641

3.  Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network.

Authors:  J Doorbar; S Ely; J Sterling; C McLean; L Crawford
Journal:  Nature       Date:  1991-08-29       Impact factor: 49.962

Review 4.  A systematic review of humoral immune responses against tumor antigens.

Authors:  Miriam Reuschenbach; Magnus von Knebel Doeberitz; Nicolas Wentzensen
Journal:  Cancer Immunol Immunother       Date:  2009-06-28       Impact factor: 6.968

5.  Human papillomavirus seropositivity and risks of head and neck cancer.

Authors:  Elaine M Smith; Justine M Ritchie; Michael Pawlita; Linda M Rubenstein; Thomas H Haugen; Lubomir P Turek; Eva Hamsikova
Journal:  Int J Cancer       Date:  2007-02-15       Impact factor: 7.396

6.  Prevalence of antibodies to human papillomavirus type 8 in human sera.

Authors:  G Steger; M Olszewsky; E Stockfleth; H Pfister
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

7.  Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery.

Authors:  D Huw Davies; Xiaowu Liang; Jenny E Hernandez; Arlo Randall; Siddiqua Hirst; Yunxiang Mu; Kimberly M Romero; Toai T Nguyen; Mina Kalantari-Dehaghi; Shane Crotty; Pierre Baldi; Luis P Villarreal; Philip L Felgner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

8.  Antibody responses to 26 skin human papillomavirus types in the Netherlands, Italy and Australia.

Authors:  Tim Waterboer; Rachel Neale; Kristina M Michael; Peter Sehr; Maurits N C de Koning; Sönke J Weißenborn; Francesca Sampogna; Damiano Abeni; Adele C Green; Jan Nico Bouwes Bavinck; Michael Pawlita
Journal:  J Gen Virol       Date:  2009-04-22       Impact factor: 3.891

9.  A genome-wide proteome array reveals a limited set of immunogens in natural infections of humans and white-footed mice with Borrelia burgdorferi.

Authors:  Alan G Barbour; Algimantas Jasinskas; Matthew A Kayala; D Huw Davies; Allen C Steere; Pierre Baldi; Philip L Felgner
Journal:  Infect Immun       Date:  2008-05-12       Impact factor: 3.441

10.  DNA microarray normalization methods can remove bias from differential protein expression analysis of 2D difference gel electrophoresis results.

Authors:  David P Kreil; Natasha A Karp; Kathryn S Lilley
Journal:  Bioinformatics       Date:  2004-03-25       Impact factor: 6.937

View more
  27 in total

Review 1.  Large screen approaches to identify novel malaria vaccine candidates.

Authors:  D Huw Davies; Patrick Duffy; Jean-Luc Bodmer; Philip L Felgner; Denise L Doolan
Journal:  Vaccine       Date:  2015-10-01       Impact factor: 3.641

2.  Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals.

Authors:  Gargi Dasgupta; Aziz A Chentoufi; Mina Kalantari; Payam Falatoonzadeh; Sookhee Chun; Chang Hyun Lim; Philip L Felgner; D Huw Davies; Lbachir BenMohamed
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling.

Authors:  Mina Kalantari-Dehaghi; Sookhee Chun; Aziz Alami Chentoufi; Jozelyn Pablo; Li Liang; Gargi Dasgupta; Douglas M Molina; Algis Jasinskas; Rie Nakajima-Sasaki; Jiin Felgner; Gary Hermanson; Lbachir BenMohamed; Philip L Felgner; D Huw Davies
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

4.  Rapid immunodiagnostics of multiple viral infections in an acoustic microstreaming device with serum and saliva samples.

Authors:  Neha Garg; Dylan Boyle; Arlo Randall; Andy Teng; Jozelyn Pablo; Xiaowu Liang; David Camerini; Abraham P Lee
Journal:  Lab Chip       Date:  2019-04-23       Impact factor: 6.799

Review 5.  Developments and Applications of Functional Protein Microarrays.

Authors:  Guan-Da Syu; Jessica Dunn; Heng Zhu
Journal:  Mol Cell Proteomics       Date:  2020-04-17       Impact factor: 5.911

6.  Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs.

Authors:  Gary Hermanson; Sookhee Chun; Jiin Felgner; Xiaolin Tan; Jozelyn Pablo; Rie Nakajima-Sasaki; Douglas M Molina; Philip L Felgner; Xiaowu Liang; D Huw Davies
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

7.  Programmable protein arrays for immunoprofiling HPV-associated cancers.

Authors:  Radwa Ewaisha; Ian Meshay; Jack Resnik; Benjamin A Katchman; Karen S Anderson
Journal:  Proteomics       Date:  2016-04-04       Impact factor: 3.984

8.  Leptospiral outer membrane protein microarray, a novel approach to identification of host ligand-binding proteins.

Authors:  Marija Pinne; James Matsunaga; David A Haake
Journal:  J Bacteriol       Date:  2012-09-07       Impact factor: 3.490

Review 9.  A systems biology approach for diagnostic and vaccine antigen discovery in tropical infectious diseases.

Authors:  Li Liang; Philip L Felgner
Journal:  Curr Opin Infect Dis       Date:  2015-10       Impact factor: 4.915

10.  Predicting antigenicity of proteins in a bacterial proteome; a protein microarray and naïve Bayes classification approach.

Authors:  Li Liang; Philip L Felgner
Journal:  Chem Biodivers       Date:  2012-05       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.